RxDoctor Payments Data

Brandylynn Turner, APRN

Family · Norwich, CTNPI 1508358649

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 59 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$227
  • Novo Nordisk$181
  • Lilly USA, LLC$151
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$98
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
  • Otsuka America Pharmaceutical, Inc.$85
  • plus $255 from 10 others

What the payments were for

  • Food & beverage$1,03696%
  • Education$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,083 in reported general payments places this provider in the 70th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$10,602
Medicare patients
41
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$25,157
RexultiBrexpiprazole13$19,673
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,384
OzempicSemaglutide15$14,287
CreonLipase/Protease/Amylase16$11,082
XareltoRivaroxaban14$8,205
JanumetSitagliptin Phos/Metformin Hcl13$7,642
MyrbetriqMirabegron12$5,388
Duloxetine Hcl35$1,543
SynthroidLevothyroxine Sodium14$1,367
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,184
Albuterol Sulfate HfaAlbuterol Sulfate33$1,174
Gabapentin68$1,106
Montelukast Sodium33$746
Trazodone Hcl37$500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$25,15721 claims
Otsuka America Pharmaceutical, Inc.Rexulti$85$19,67313 claims
GSKTrelegy Ellipta$13$19,38420 claims
Novo NordiskOzempic$181$14,28715 claims
AbbVieCreon, Synthroid$227$12,44830 claims
MerckJanumet$15$7,64213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,596 family providers in Connecticut.

Other family in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →